Principles of Immunosuppression

The contract between this chapter and the reader.

1. 1. State the goal and central balance of immunosuppression.
2. 2. Map the immunosuppressants to the three signals of T-cell activation.
3. 3. Explain the rationale for combination therapy.
4. 4. Explain the induction-then-maintenance strategy.
5. 5. Describe the purpose of induction.
6. 6. Distinguish depleting from non-depleting induction agents.
7. 7. Choose induction by immunologic risk.
8. 8. Recognise the adverse-effect classes of immunosuppression.
9. 9. Recognise the induction-specific adverse effects.

A sixty-second reading. Each bullet stands alone.

• The goal of immunosuppression is to prevent rejection while minimising infection, malignancy, and drug toxicity.
• Immunosuppressants act on the three signals of T-cell activation, plus antiproliferation, lymphocyte depletion, and broad steroid effects.
• Combination therapy blocks multiple signals at lower individual doses, giving synergy with less toxicity.
• The alloresponse is strongest early, so immunosuppression is intense at induction and lower for maintenance.
• Induction is intense peri-transplant immunosuppression that covers the highest-risk early period and allows lower or delayed maintenance.
• Depleting induction agents — anti-thymocyte globulin and alemtuzumab — deplete lymphocytes and are used in higher immunologic risk.
• Non-depleting induction (basiliximab, an interleukin-2-receptor antibody) is well tolerated and used in standard risk.
• Induction is chosen by immunologic risk — depleting for high risk, an IL-2-receptor antibody for standard.
• Too little immunosuppression causes rejection; too much causes infection, malignancy, and toxicity.
• Anti-thymocyte globulin can cause cytokine release and prolonged lymphopenia.
• Depleting induction raises the risk of later infection and malignancy, so prophylaxis is added.
• A depleting induction can allow calcineurin-inhibitor introduction to be delayed, useful in delayed graft function.
• Maintenance immunosuppression is typically triple therapy, detailed in the next chapter.

The medical core. An expert should agree the principles of immunosuppression and induction are fully covered here.

Why it matters at the bedside

Immunosuppression is a balancing act played for life. Too little and the graft is rejected; too much and the patient is delivered to infection and cancer. Every regimen is an attempt to walk that line — hardest at the start, when the immune response is fiercest, and recalibrated ever after. This chapter sets out the strategy and the agents that open it: induction.

The goal and the balance

• The aim is simple to state and hard to achieve: suppress the alloresponse enough to protect the graft, but no more than necessary, because the cost of over-suppression is infection, malignancy, and drug toxicity. Every decision in transplant immunosuppression is a point on this rejection-versus-toxicity line.

The targets: the three signals

• The drugs map onto the immunology of the first chapter. Signal 1 (antigen recognition, leading to interleukin-2) is targeted by calcineurin inhibitors; signal 2 (costimulation) by belatacept; signal 3 (cytokine-driven proliferation) by mTOR inhibitors and interleukin-2-receptor antibodies. Beyond the three signals, antimetabolites block lymphocyte proliferation, depleting agents remove lymphocytes outright, and corticosteroids act broadly. Knowing the target explains the drug.

The rationale for combination therapy

• Immunosuppression is given in combination, not as a single agent, because blocking several points in the activation pathway at once allows each drug to be used at a lower dose — synergy with less individual toxicity. The standard maintenance regimen layers a calcineurin inhibitor, an antimetabolite, and a steroid (the next chapter), each hitting a different target.

Induction then maintenance

• Because the alloresponse is strongest in the first weeks — and the risk of acute rejection highest then — immunosuppression is front-loaded: an intense induction phase around the transplant, then a lower, sustainable maintenance phase for life. The strategy matches the intensity of suppression to the intensity of the threat over time.

The purpose of induction

• Induction is a burst of intense immunosuppression given at the time of transplant, when the immune system most threatens the new graft and any donor-specific antibody is most dangerous. It reduces early acute rejection and, by covering this period, allows the maintenance regimen to be lower or — importantly — to have the calcineurin inhibitor delayed when the graft is vulnerable, as in delayed graft function.

Depleting versus non-depleting induction

• Induction agents fall into two camps. Depleting agents — polyclonal anti-thymocyte globulin and the anti-CD52 antibody alemtuzumab — physically remove lymphocytes, giving powerful, prolonged suppression at the cost of greater later infection and malignancy risk. Non-depleting induction — basiliximab, an interleukin-2-receptor (anti-CD25) antibody — blocks activated T cells without depletion, is well tolerated, and suffices for standard risk.

Choosing induction by risk

• The choice follows the immunologic risk established at evaluation (the histocompatibility chapter). High-risk recipients — with donor-specific antibody, a high cPRA, or a re-transplant — receive a depleting agent for its greater potency; standard- and low-risk recipients receive an interleukin-2-receptor antibody. A depleting agent is also chosen when delaying the calcineurin inhibitor is desirable, as in delayed graft function.

The adverse-effect classes

• The harms of immunosuppression cluster into three classes that recur throughout the rest of this book: infection (especially opportunistic — its own chapter, with prophylaxis particularly after depletion), malignancy (skin cancer and post-transplant lymphoproliferative disorder — its own chapter), and drug-specific toxicities (developed per agent in the maintenance chapter). The intensity of suppression sets the level of all three.

Induction-specific adverse effects

• Induction adds its own short-term hazards. Anti-thymocyte globulin can provoke a cytokine-release reaction during infusion (fever, chills, hypotension — mitigated by premedication and slow infusion) and a prolonged lymphopenia that heightens later infection risk; both depleting agents demand vigilant infection prophylaxis. Interleukin-2-receptor antibodies are, by contrast, notably well tolerated.

Five fully-built tables.

Table A — The targets and drug classes

Table B — Induction agents

Table C — Choosing induction by risk

Table D — The central balance

Table E — Adverse-effect classes

Visualise & Map

Causal chains, each ending in a named action.

Chain 1 — Why combination therapy

Three signals to block → hit several at lower individual doses → synergy with less toxicity → ACTION: use combination immunosuppression, not a single agent.

Chain 2 — Why front-load

The alloresponse is strongest early → most rejection risk in the first weeks → intense induction then lower maintenance → ACTION: front-load immunosuppression and taper to maintenance.

Chain 3 — Matching potency to risk

Higher immunologic risk → greater alloresponse → stronger (depleting) induction needed → ACTION: match induction agent to the immunologic risk.

Chain 4 — The cost of suppression

More immunosuppression → weaker immune defence and surveillance → more infection and malignancy → ACTION: titrate to the minimum effective immunosuppression and add prophylaxis.

Chain 5 — Sparing the injured graft

Depleting induction covers the early period → maintenance can be lighter or delayed → the nephrotoxic CNI can be postponed → ACTION: use depleting induction to delay CNI in delayed graft function.

Numbered rules. These numbers are the cross-reference handle for the cases and flowcharts.

Clinical Reasoning

Four cases. Each stops you at a decision before it answers it.

Every mechanism from Level 3 earns a bedside consequence and an action.

Exhaustive. Every rule in the chapter is here.

Safety & Evidence

Panel A — Red flags

Panel B — NEVER DO

Anti-patterns clinicians fall into. Each becomes a Level 22 distractor.

The grade reflects strength of evidence, not importance.

Patient Decisions

Outcomes as natural frequencies. Figures are representative; the direction of effect is given where precise numbers are uncertain.

Apply & Test

Copy-paste chart notes that map to the real decisions in this chapter.

Template 1 — Induction prescription note

• Immunologic risk: high (DSA / high cPRA / re-transplant) / standard.
• Induction agent: depleting (ATG / alemtuzumab) / IL-2R antibody (basiliximab).
• Rationale (incl. DGF / CNI-sparing if relevant): ___.
• Premedication (for ATG) and infusion plan: ___.
• Infection prophylaxis (especially after depletion): ___.

Template 2 — Immunosuppression balance note

• Current regimen and phase (induction / maintenance): ___.
• Evidence of under-suppression (rejection): ___.
• Evidence of over-suppression (infection / malignancy): ___.
• Adjustment toward the minimum effective regimen: ___.
• Prophylaxis and monitoring plan: ___.

Pre-rounds compression. Rules only.

Active recall. At least one card per objective.

Micro-teaching for rounds. Two scenarios, five steps each.

Nine items, each anchored in this chapter. At least one per objective.